Superworth

Tarsus Pharmaceuticals price to sales ratio TARS

Market value divided by revenue over the last twelve months, since 2024.

Today, Nov 2, 2026
5.3×
3-year median
9.3×
Against its 3-year history
15th
percentile: 0 is its lowest day, 100 its highest
3-year range
4.7× to 72.5×
Peer median
7.0×

Tarsus Pharmaceuticals' price to sales ratio is 5.3× as of Nov 2, 2026.

That is below its 3-year median of 9.3×, lower than on 85% of days in the last 3 years.

Over that time it ranged from 4.7× in Jul 2026 to 72.5× in Mar 2024.

The median for 10 biotech stocks of a similar size is 7.0×.

Price to sales ratio over time

Open the interactive chart, with overlays and comparisons

Year by year

YearEnd of yearLowHigh
2026 so far5.3×4.7×9.4×
20259.5×6.8×16.4×
202416.2×11.6×72.5×

Against its peers

Companies in Biotechnology nearest Tarsus Pharmaceuticals' size, closest first, today.

CompanyPrice to sales ratio
TARSTarsus Pharmaceuticals5.3×
ADMAAdma Biologics4.8×
VCELVericel6.8×
KRYSKrystal Biotech19.9×
RGENRepligen12.4×
TECHBIO-TECHNE9.4×
MGTXMeiraGTx2.3×
HALOHalozyme Therapeutics8.8×
NBIXNeurocrine Biosciences4.4×
EXELExelixis7.1×
ALNYAlnylam Pharmaceuticals4.4×
Peer median7.0×

Where Tarsus Pharmaceuticals ranks

What the price to sales ratio tells you

Market value divided by revenue over the last twelve months. Useful for companies with little or no profit yet, since sales are harder to make negative than earnings.

Ignores margins entirely. A software company at 10× sales with 30% margins can be cheaper than a grocer at 1× sales with 2% margins.

More on Tarsus Pharmaceuticals

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.